<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852576</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00158121</org_study_id>
    <nct_id>NCT03852576</nct_id>
  </id_info>
  <brief_title>Phase 1B Study of KSP/QRH Dimer for Detection of Neoplasia in the Esophagus</brief_title>
  <official_title>Phase 1B In-vivo Study of KSP/QRH Heptapeptide Dimer for Detection of Neoplasia in the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this feasibility study is to develop new technologies for improved&#xD;
      detection of Barrett's neoplasia using the scanning fiber endoscope (SFE) imaging system.&#xD;
      This study will combine the use of a fluorescent-labeled peptide dimer that bind specifically&#xD;
      to pre-cancerous mucosa in the esophagus for use as a novel imaging agent to guide endoscopic&#xD;
      biopsy or endoscopic mucosal resection (EMR). This Phase 1B study will be used to provide&#xD;
      early evidence of efficacy for the topical application of a peptide dimer that binds to&#xD;
      molecular targets, including EGFR and HER2, that are specific for esophageal dysplasia. A&#xD;
      dimer is needed because cancer in the esophagus is genetically heterogeneous. QRH binds&#xD;
      specifically to Epidermal Growth Factor Receptor (EGFR), and KSP binds specifically to Human&#xD;
      Epithelial Growth Factor Receptor (HER2). The study will look at peptide binding in subjects&#xD;
      with known or suspected Barrett's esophagus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binding of KSP/QRH dimer to EGFR and HER2</measure>
    <time_frame>2 years</time_frame>
    <description>Validation of the dimer to EGFR and HER2 using target-to-background ratio of the suspicious region compared to the background</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SFE ability to detect dimer by SNR</measure>
    <time_frame>2 years</time_frame>
    <description>SFE (scanning fiber endoscope) imaging system will be used to image the dimer on the area of interest using signal-to-noise ratio (SNR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SFE ability to detect dimer by fluorescence T/B ratio</measure>
    <time_frame>2 years</time_frame>
    <description>SFE (scanning fiber endoscope) imaging system will be used to image the dimer on the area of interest using fluorescence tumor-to-background (T/B) ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SFE ability to detect dimer with contrast</measure>
    <time_frame>2 years</time_frame>
    <description>SFE (scanning fiber endoscope) imaging system will be used to image the dimer on the area of interest using contrast</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>Esophagus sprayed with KSP/QRH dimer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSP/QRH dimer</intervention_name>
    <description>KSP-QRH-E3-IRDye800 (Peptide 919288G)</description>
    <arm_group_label>Esophagus sprayed with KSP/QRH dimer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has known or suspected Barrett's esophagus&#xD;
&#xD;
          -  Scheduled for a clinically-indicated, upper endoscopy&#xD;
&#xD;
          -  Subject is medically cleared for the procedure (e.g. washout for anticoagulants,&#xD;
             co-morbidities)&#xD;
&#xD;
          -  Age 18 to 100 years&#xD;
&#xD;
          -  Willing and able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known allergy or negative reaction to the near infrared fluorophore&#xD;
             IRDye800CW, or derivatives&#xD;
&#xD;
          -  Subjects on active chemotherapy or radiation treatment&#xD;
&#xD;
          -  Pregnant or trying to conceive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danielle K Turgeon, MD</last_name>
    <phone>734-764-6860</phone>
    <email>kturgeon@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine Brady, MBA</last_name>
    <phone>734-647-4794</phone>
    <email>embrady@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle K Turgeon, MD</last_name>
      <phone>734-674-6860</phone>
      <email>kturgeon@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elaine M Brady, MBA</last_name>
      <phone>734-647-4794</phone>
      <email>embradt@med.umich.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Danielle Kim Turgeon</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

